Corvus Pharmaceuticals, Inc.CRVSNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank64
3Y CAGR+9.6%
5Y CAGR-0.4%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+9.6%/yr
vs -9.8%/yr prior
5Y CAGR
-0.4%/yr
Recent acceleration
Acceleration
+19.4pp
Accelerating
Percentile
P64
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $42.87M | +55.6% |
| 2024 | $27.55M | +17.7% |
| 2023 | $23.41M | -28.1% |
| 2022 | $32.56M | -15.7% |
| 2021 | $38.63M | -11.7% |
| 2020 | $43.76M | -10.4% |
| 2019 | $48.85M | -0.7% |
| 2018 | $49.22M | -12.9% |
| 2017 | $56.52M | +52.9% |
| 2016 | $36.98M | - |